News ESC26: Heart attack reclassification rights gender imbalance New definitions of myocardial infarction released at ESC 2026 recognise that there are different causes - and could lead to better treatment of women.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
R&D Why physiological pacing is changing the future of cardiac r... Increasingly, electrophysiologists are exploring approaches that activate the heart through its intrinsic conduction pathways.
News ESC: Study says GLP-1s treat heart failure AND cut emissions Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.
News New heart attack data boost AZ’s Brilinta A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.